[Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
D001545:Benserazide / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D004357:Drug Synergism; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide; D002262:Carboxy-Lyases
La nostra esperienza nel trattamento del morbo di Parkinson con l'associazione L-dopa plus 4-4602